UA115333C2 - Parenteral esmolol formulation - Google Patents
Parenteral esmolol formulationInfo
- Publication number
- UA115333C2 UA115333C2 UAA201413014A UAA201413014A UA115333C2 UA 115333 C2 UA115333 C2 UA 115333C2 UA A201413014 A UAA201413014 A UA A201413014A UA A201413014 A UAA201413014 A UA A201413014A UA 115333 C2 UA115333 C2 UA 115333C2
- Authority
- UA
- Ukraine
- Prior art keywords
- esmolol hydrochloride
- solution
- ready
- pure
- solvent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
A parenteral formulation of esmolol hydrochloride for use in the treatment of a patient suffering from tachycardia comprising a lyophilized powder consisting of pure esmolol hydrochloride, wherein said powder is reconstituted to obtain a ready-to-use i.v. solution of esmolol hydrochloride at a concentration of 20-100 mg/mL, and said i.v. solution is directly administered to the patient, and further a method of producing a ready-to-use i.v. solution of esmolol hydrochloride by reconstituting a lyophilized powder consisting of pure esmolol hydrochloride with a solvent, characterized in that said solvent is an i.v. solvent devoid of alcohol or a buffer excipient, in an amount necessary to obtain a ready-to-use i.v. solution at a concentration of 20-100 mg/mL, and the ready-to-use i.v. solution containing a parenteral formulation of 20-100 mg/mL pure esmolol hydrochloride in an infusion device or consisting of a parenteral formulation of 20-100 mg/mL pure esmolol hydrochloride, WFI and/or saline solution, devoid of any alcohol or buffer excipients.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12167443 | 2012-05-10 | ||
| PCT/EP2013/059594 WO2013167657A1 (en) | 2012-05-10 | 2013-05-08 | Parenteral esmolol formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA115333C2 true UA115333C2 (en) | 2017-10-25 |
Family
ID=48407551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201413014A UA115333C2 (en) | 2012-05-10 | 2013-05-08 | Parenteral esmolol formulation |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US20150087704A1 (en) |
| EP (1) | EP2846776B1 (en) |
| JP (1) | JP6220383B2 (en) |
| CN (1) | CN104379134A (en) |
| AU (1) | AU2013258031B2 (en) |
| BR (1) | BR112014027870B1 (en) |
| CA (1) | CA2872953C (en) |
| CL (1) | CL2014003028A1 (en) |
| DK (1) | DK2846776T3 (en) |
| EA (1) | EA032344B1 (en) |
| ES (1) | ES2794093T3 (en) |
| HK (1) | HK1204265A1 (en) |
| HR (1) | HRP20200897T1 (en) |
| HU (1) | HUE049314T2 (en) |
| IL (1) | IL235497A0 (en) |
| LT (1) | LT2846776T (en) |
| MA (1) | MA37500B1 (en) |
| MX (1) | MX2014013556A (en) |
| MY (1) | MY173900A (en) |
| NZ (1) | NZ701429A (en) |
| PH (1) | PH12014502494A1 (en) |
| PL (1) | PL2846776T3 (en) |
| PT (1) | PT2846776T (en) |
| SI (1) | SI2846776T1 (en) |
| TN (1) | TN2014000464A1 (en) |
| UA (1) | UA115333C2 (en) |
| WO (1) | WO2013167657A1 (en) |
| ZA (1) | ZA201408149B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019122157A1 (en) * | 2017-12-21 | 2019-06-27 | Ipsol Ag | A lyophilisate comprising esmolol and adenosine for use in cardioplegia |
| CN111848420A (en) * | 2020-07-22 | 2020-10-30 | 杭州煌森生物科技有限公司 | Novel crystal form of esmolol hydrochloride and preparation method thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6310094B1 (en) * | 2001-01-12 | 2001-10-30 | Baxter International Inc. | Ready-to-use esmolol solution |
| TWI277414B (en) | 2001-01-12 | 2007-04-01 | Baxter Int | Esmolol formulation |
| SE0401842D0 (en) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| JPWO2007026771A1 (en) * | 2005-08-31 | 2009-03-12 | 小野薬品工業株式会社 | Injection for infusion |
| US20080293814A1 (en) | 2007-05-22 | 2008-11-27 | Deepak Tiwari | Concentrate esmolol |
| US20100311738A1 (en) | 2007-12-21 | 2010-12-09 | Aop Orphan Pharmaceuticals Ag | Pharmaceutical Composition For The Parenteral Administration Of Ultrashort-Effective Beta-Adrenoreceptor Antagonists |
| CN102106846A (en) * | 2009-12-23 | 2011-06-29 | 南京海辰药业有限公司 | Levogyration esmolol hydrochloride medicinal compositions and preparation method thereof |
-
2013
- 2013-05-08 MY MYPI2014703249A patent/MY173900A/en unknown
- 2013-05-08 LT LTEP13721740.2T patent/LT2846776T/en unknown
- 2013-05-08 PL PL13721740T patent/PL2846776T3/en unknown
- 2013-05-08 MX MX2014013556A patent/MX2014013556A/en active IP Right Grant
- 2013-05-08 JP JP2015510815A patent/JP6220383B2/en active Active
- 2013-05-08 SI SI201331732T patent/SI2846776T1/en unknown
- 2013-05-08 NZ NZ701429A patent/NZ701429A/en unknown
- 2013-05-08 US US14/398,312 patent/US20150087704A1/en not_active Abandoned
- 2013-05-08 CN CN201380028099.XA patent/CN104379134A/en active Pending
- 2013-05-08 EA EA201491841A patent/EA032344B1/en not_active IP Right Cessation
- 2013-05-08 HU HUE13721740A patent/HUE049314T2/en unknown
- 2013-05-08 CA CA2872953A patent/CA2872953C/en active Active
- 2013-05-08 DK DK13721740.2T patent/DK2846776T3/en active
- 2013-05-08 AU AU2013258031A patent/AU2013258031B2/en active Active
- 2013-05-08 EP EP13721740.2A patent/EP2846776B1/en active Active
- 2013-05-08 UA UAA201413014A patent/UA115333C2/en unknown
- 2013-05-08 ES ES13721740T patent/ES2794093T3/en active Active
- 2013-05-08 PT PT137217402T patent/PT2846776T/en unknown
- 2013-05-08 WO PCT/EP2013/059594 patent/WO2013167657A1/en active Application Filing
- 2013-05-08 BR BR112014027870-9A patent/BR112014027870B1/en active IP Right Grant
-
2014
- 2014-10-31 TN TN2014000464A patent/TN2014000464A1/en unknown
- 2014-11-04 IL IL235497A patent/IL235497A0/en active IP Right Grant
- 2014-11-05 MA MA37500A patent/MA37500B1/en unknown
- 2014-11-07 CL CL2014003028A patent/CL2014003028A1/en unknown
- 2014-11-07 ZA ZA2014/08149A patent/ZA201408149B/en unknown
- 2014-11-07 PH PH12014502494A patent/PH12014502494A1/en unknown
-
2015
- 2015-05-19 HK HK15104754.1A patent/HK1204265A1/en unknown
-
2017
- 2017-07-28 US US15/663,645 patent/US20170326095A1/en not_active Abandoned
-
2020
- 2020-06-04 HR HRP20200897TT patent/HRP20200897T1/en unknown
-
2022
- 2022-01-24 US US17/582,945 patent/US20220249424A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ701915A (en) | High-concentration monoclonal antibody formulations | |
| NZ630790A (en) | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes | |
| NZ595767A (en) | Composition for the treatment of prostate cancer | |
| MX2020014208A (en) | Optimised subcutaneous therapeutic agents. | |
| NZ702342A (en) | Pharmaceutical formulation | |
| MX348418B (en) | Ocular composition containing bromfenac with increased bioavailability. | |
| EA201691055A1 (en) | PREPARATIONS AND METHODS OF TREATMENT OF GD2-POSITIVE CANCER | |
| MX2015009546A (en) | Increased dosage of efavirenz for the treatment of cancer. | |
| PH12014502494B1 (en) | Parenteral esmolol formulation | |
| PH12017501005A1 (en) | Injectable formulations of paracetamol | |
| UA69674U (en) | method for treatment of erythematous-bullous erysipelas | |
| RU2012156689A (en) | METHOD FOR TREATING AN ENDOGENOUS INTOXICATION SYNDROME DUE TO HYPERPROTEOLYSIS | |
| RU2013142835A (en) | METHOD FOR TREATING ISCHEMIC STROKE | |
| UA79052U (en) | method for immunotherapy in exacerbations of chronic bronchitis in patients with insulin resistance | |
| UA69682U (en) | method for prevention of exacerbations of hepatitis A in adult patients | |
| UA64881U (en) | method for treatment of hepatic insufficiency of patirns with the liver trauma | |
| UA69975U (en) | Method for correction of cellular immunity in patients with nonalcoholic steatohepatitis | |
| RU2012110137A (en) | METHOD FOR TREATING AN INSULIN RESISTANCE | |
| TH155633A (en) | Esmolol injectable formulation | |
| UA69978U (en) | Method for treatment of patients with primary erysipelas | |
| UA89638U (en) | Method for treating aged patients with syndrome of vascular cognitive impairment | |
| UA88719U (en) | Method for treating the vestibular syndrome (dizziness) in patients with beer addiction at remission stage | |
| UA69683U (en) | Method for treatment of patients with steatohepatitis | |
| UA69267U (en) | method for immune correction of patients with lichen ruber planus of mucous membranes | |
| GR1008260B (en) | Intravenous formulation of linezolid and method for preparation thereof |